Cytosurge Appoints Luba Greenwood To Board Of Directors To Strengthen AI-Driven Drug Discovery Growth

Cytosurge, a biotechnology company pioneering the field of Same-Cell Biology, has announced the appointment of Luba Greenwood, J.D., to its Board of Directors, effective July 9, 2026. A highly respected biotechnology executive, investor, and entrepreneur, Greenwood brings decades of experience across biotechnology, pharmaceuticals, life sciences, artificial intelligence, and deep technology. Her appointment comes at an important stage in Cytosurge's growth as the company expands its proprietary technology platform, broadens its commercial services, and strengthens its ability to generate causal biological data that supports the next generation of AI-powered drug discovery.

Greenwood currently serves as the Chief Executive Officer of Mwyngil Therapeutics and is a member of several prominent industry boards, including MassBio. Throughout her career, she has built a strong reputation for supporting scientific innovation, company growth, and investment in emerging technologies. She also founded and led the venture fund at Dana-Farber Cancer Institute, gaining significant experience in identifying and supporting promising life science companies. Her expertise in venture capital, business strategy, and biotechnology is expected to help Cytosurge expand its presence in the United States while strengthening relationships with strategic investors and industry partners.

Cytosurge is focused on solving one of the biggest challenges facing AI-driven drug discovery. Most artificial intelligence models currently rely on endpoint data, which captures the final outcome of biological processes but often provides only correlations rather than clear evidence of cause and effect. This limitation reduces the ability of researchers to accurately predict how potential drug candidates will perform during development.

To address this challenge, Cytosurge has developed its patented FluidFM® technology, which powers the FluidFM® OMNIUM platform. The technology allows scientists to safely collect microscopic samples from living cells without destroying or harming them. This unique capability enables researchers to analyze the exact same living cell before and after a treatment or biological intervention. Instead of comparing different cells, scientists can directly observe how a single cell responds over time, generating high-quality causal biological data. This innovative approach has led Cytosurge to introduce the concept of Same-Cell Biology, providing researchers with a more accurate understanding of cellular responses that can improve drug discovery and biomedical research.

Commenting on her appointment, Greenwood said she is honored to join Cytosurge's Board of Directors and contribute to a company that is establishing an entirely new category of biological research. She explained that Same-Cell Biology makes it possible to observe the condition of a living cell both before and after an intervention, transforming uncertainty into direct biological evidence. She also praised the company's multidisciplinary team of engineers, biologists, and data scientists, stating that their shared commitment to understanding individual cellular responses will help advance the development of safer and more effective medicines.

Greenwood also emphasized the growing importance of causal biological data in artificial intelligence-based drug discovery. She noted that many AI platforms are being trained on endpoint datasets that reveal associations between biological events but fail to explain why those changes occur. According to her, simply increasing computing power or expanding AI models cannot overcome this limitation. She believes Cytosurge's proprietary technology is uniquely positioned to generate the causal data that has been missing from drug discovery, creating an essential foundation for the future of digital biology and more reliable AI-driven therapeutic development.

Simon Egli, Chief Executive Officer of Cytosurge, welcomed Greenwood to the Board and described her appointment as an important milestone for the company. He said the pharmaceutical industry is increasingly recognizing that advances in artificial intelligence must be supported by accurate biological evidence to improve drug development outcomes. Egli added that Greenwood's extensive experience in biotechnology, investment, and business development makes her an ideal addition to the Board as Cytosurge continues expanding its technology platform, commercial operations, and presence in the United States.

Cytosurge has already begun commercializing its technology through its Live-seq as a Service offering and is actively collaborating with pharmaceutical companies on projects involving oncology biomarker discovery and target validation. The company's FluidFM® technology is currently installed in more than 140 research laboratories at leading universities, research institutes, and pharmaceutical organizations around the world. Its scientific credibility is supported by more than 130 peer-reviewed publications, including validation in Nature, demonstrating broad acceptance within the global research community.

As its technology adoption continues to grow, Cytosurge is building a comprehensive collection of causal biological data that can support the development of advanced computational models for drug discovery. By helping pharmaceutical researchers identify more effective drug targets, evaluate biological responses with greater precision, and determine optimal treatment doses, the company aims to improve the efficiency and success of future medicine development while advancing the capabilities of AI-driven biomedical research.